FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t... September 8, 2020 How Adolescent and Young Adult Cancer Survivors Can Cope With the... November 17, 2022 What to Know About Biomarker Testing for Lung Cancer: An Expert... June 9, 2022 Reduction Not Only in Recurrences, but Also in Mortality, Observed for... December 20, 2022 Load more HOT NEWS Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal Happy 29th Birthday OncoLink! How Finding the Right Primary Care Physician During Cancer Has Helped... ESMO Congress 2021, 16-21 September
